

1 **Delta variants of SARS-CoV-2 cause significantly increased**
2 **vaccine breakthrough COVID-19 cases in Houston, Texas**

3
4
5 Paul A. Christensen,^{*,†,‡} Randall J. Olsen,^{*,†,‡} S. Wesley Long,^{*,†,‡} Sishir Subedi,[†] James
6 J. Davis,^{§,¶} Parsa Hodjat,[†] Debbie R. Walley,[†] Jacob C. Kinskey,[†] Matthew Ojeda
7 Saavedra,[†] Layne Pruitt,[†] Kristina Reppond,[†] Madison N. Shyer,[†] Jessica Cambric,[†]
8 Ryan Gadd,[†] Rashi M. Thakur,[†] Akanksha Batajoo,[†] Regan Mangham,[†] Sindy Pena,[†]
9 Trina Trinh,[†] Prasanti Yerramilli,[†] Marcus Nguyen,^{§,¶} Robert Olson,^{§,¶} Richard Snehal,[†]
10 Jimmy Gollihar,^{†,#} James M. Musser.^{†,‡,**}

11

12 **Contributed equally;*

13 *†Laboratory of Human Molecular and Translational Human Infectious Diseases, Center*
14 *for Infectious Diseases, Houston Methodist Research Institute and Department of*
15 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas 77030;*

16 *‡Department of Pathology and Laboratory Medicine, Weill Cornell Medical College,*
17 *1300 York Avenue, New York City, New York 10065;*

18 *§Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801*
19 *South Ellis Avenue, Chicago, Illinois, 60637;*

20 ¶*Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South*

21 *Cass Avenue, Lemont, Illinois, 60439;*

22 *#DEVCOM Army Research Laboratory-South, Austin, Texas 78712*

23

24 ***Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*

25 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*

26 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

27 jmmusser@houstonmethodist.org

28

29 Running head: Delta variants and vaccine breakthrough

30

31 Disclosures: None.

32

33 Number of text pages: 15

34 Number of tables: 3

35 Number of figures: 4

36

37 Funding: This project was supported by the Houston Methodist Academic Institute

38 Infectious Diseases Fund; and supported in whole or in part with federal funds from the

39 National Institute of Allergy and Infectious Diseases, National Institutes of Health,

40 Department of Health and Human Services, under Contract No. 75N93019C00076

41 (J.J.D. and R.O.).

42

43 **Abstract**

44 Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19
45 pandemic. Delta variants of concern are now the focus of intense international attention
46 because they are causing widespread COVID-19 disease globally and are associated
47 with vaccine breakthrough cases. We sequenced the genomes of 16,965 SARS-CoV-2
48 from samples acquired March 15, 2021 through September 20, 2021 in the Houston
49 Methodist hospital system. This sample represents 91% of all Methodist system COVID-
50 19 patients during the study period. Delta variants increased rapidly from late April
51 onward to cause 99.9% of all COVID-19 cases and spread throughout the Houston
52 metroplex. Compared to all other variants combined, Delta caused a significantly higher
53 rate of vaccine breakthrough cases (23.7% for Delta compared to 6.6% for all other
54 variants combined). Importantly, significantly fewer fully vaccinated individuals required
55 hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low
56 median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was
57 closely similar to the median Ct value for unvaccinated patients with COVID-19 caused
58 by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2
59 to others. Patients infected with Alpha and Delta variants had several significant
60 differences. Our integrated analysis emphasizes that vaccines used in the United States
61 are highly effective in decreasing severe COVID-19 disease, hospitalizations, and
62 deaths.

63 [Introduction]
64
65
66 Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY.3, and AY.4
67 are the focus of intense international concern because they are causing widespread
68 COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere
69 ([https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
70 [info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed: August 18, 2021;
71 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed:
72 August 18, 2021)¹. For example, Delta has replaced the Alpha variant in the United
73 Kingdom, previously the cause of virtually all COVID-19 cases in that country
74 ([https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)
75 [13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)), last accessed August 18, 2021;
76 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021)
77 [anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021), last accessed
78 August 18, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also
79 have become of considerable public health and biomedical concern worldwide²⁻⁶. To
80 study Delta spread and vaccine breakthrough cases in metropolitan Houston, we
81 sequenced the genomes of 16,965 SARS-CoV-2 from patient samples acquired March
82 15, 2021 through September 20, 2021 using an Illumina NovaSeq 6000 instrument and
83 methods described previously^{7, 8}. This period includes the time from initial identification
84 of Delta-related VOCs in late April in our large Houston Methodist healthcare system
85 until Delta VOCs continuously caused the supermajority (99.9%) of all new cases. The
86 sequenced sample is 91% of the 18,736 total COVID-19 cases diagnosed in our health
87 system during the study period. We also compared characteristics of patients infected

88 with Alpha and Delta VOCs, an analysis that identified several significant differences
89 between patients infected with these two variants.

90

91

92 **Materials and Methods**

93

94 **Patient Specimens**

95

96 Specimens were obtained from registered patients at Houston Methodist hospitals,
97 associated facilities (e.g., urgent care centers), and institutions in the Houston
98 metropolitan region that use our laboratory services. The great majority of individuals
99 had signs or symptoms consistent with COVID-19 disease. For analyses focusing on
100 the Delta family variants, a comprehensive sample of genomes obtained from March 15,
101 2021 through September 20, 2021 was used. This time frame was chosen because it
102 represents the period during which the downturn of our third wave was occurring, and
103 soon after we identified the first Delta variant case in our health care system.

104 Subsequently, Delta variants increased rapidly to continuously cause 99.9% of all new
105 cases. The study included 16,965 unique patients identified in this time frame for whom
106 we had SARS-CoV-2 genome sequences. For analyses comparing features of patients
107 infected with the Delta variants and Alpha VOC, a comprehensive sample of genomes
108 obtained from January 1, 2021 through September 20, 2021 was used. This time frame
109 represents the period during which we identified the first Alpha variant case in our

110 health care system. This VOC increased rapidly and peaked, and then decreased to
111 cause less than 1% of all cases in the region. This part of the study included 28,560
112 unique patients identified in the January 1, 2021 through September 20, 2021 period.
113 The work was approved by the Houston Methodist Research Institute Institutional
114 Review Board (IRB1010-0199).

115

116 SARS-CoV-2 Molecular Diagnostic Testing

117

118 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
119 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
120 using assays granted Emergency Use Authorization (EUA) from the FDA
121 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
122 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple
123 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
124 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
125 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-
126 2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using
127 the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic
128 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
129 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were
130 performed on material obtained from nasopharyngeal swabs immersed in universal
131 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
132 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

133 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last
134 [accessed June 7, 2021](#)).

135

136 SARS-CoV-2 Genome Sequencing

137

138 Libraries for whole SARS-CoV-2 genome sequencing were prepared according to
139 version 3 or version 4 ([https://community.artic.network/t/sars-cov-2-version-4-scheme-
140 release/312](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312), last accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing
141 protocol. Our semi-automated workflow described previously^{7,8} employed BioMek i7
142 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS automated
143 liquid handlers (FORMULATRIX). Short sequence reads were generated with a
144 NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis in the
145 study period, we included some genome sequences reported in a recent publication.⁸

146

147 SARS-CoV-2 Genome Sequence Analysis and Identification of Variants

148

149 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
150 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,
151 2021, requires registration). The One Codex SARS-CoV-2 variant calling and
152 consensus assembly pipeline was used to assemble all sequences
153 (<https://github.com/onecodex/sars-cov-2.git>, last accessed June 7, 2021) using default
154 parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-
155 r116 for sequence trimming (<https://github.com/lh3/seqtk.git>, last accessed June 7,

156 2021); minimap version 2.1 for aligning reads against reference genome Wuhan-Hu-1
157 (NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar
158 version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and
159 variants of interest (VOIs) were identified based on genome sequence data and
160 designated by Pangolin v. 3.1.11 with pangoLEARN module 2021-08-09 ([https://cov-](https://cov-lineages.org/resources/pangolin.html)
161 [lineages.org/resources/pangolin.html](https://cov-lineages.org/resources/pangolin.html), last accessed August 18, 2021).

162 There is a known problem with the ARTIC V3 primer set that results in lack of
163 detection or ambiguity of the G142D and D950N single nucleotide variants, even though
164 these amino acid changes (142D and 950N) are present in the overwhelming majority of
165 B.1.617.2 Delta variant isolates ([https://community.artic.network/t/sars-cov-2-version-4-](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312)
166 [scheme-release/312](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312), last accessed September 1, 2021, [https://outbreak.info/compare-](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2)
167 [lineages?pango=B.1.617.2&gene=S&threshold=0.2](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2), last accessed September 1, 2021).
168 After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes
169 contained both 142D and 950N polymorphisms except for four isolates, two of which
170 lacked 142D and two which lacked 950N. We recently reported an analysis that
171 confirmed the previously identified ARTIC V3 problem⁹. Thus, for the Delta isolates
172 presented here, virtually all samples sequenced with ARTIC V3 are presumed to have
173 G142D and D950N.

174

175 Patient Metadata and Geospatial Analysis

176

177 Patient metadata (**Table 1**, **Table 2**, **Table 3**) were acquired from the electronic medical
178 record by standard informatics methods. Patient home address zip codes were used to

179 visualize the geospatial distribution of spread for each VOC and VOI. Figures were
180 generated with Tableau version 2020.3.4 ([Tableau Software, LLC, Seattle, WA](#)). A
181 vaccination breakthrough case was defined as a PCR-positive sample from a patient
182 obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or
183 Moderna mRNA vaccines) was completed. For some cases, manual chart review was
184 conducted to resolve discrepancies or ambiguities.

185

186

187 **Results**

188

189 **Delta Epidemiologic Wave**

190

191 The first Houston Methodist patient infected with a Delta family variant was identified in
192 mid-April 2021, a time when the Alpha VOC was responsible for most COVID-19 cases
193 in metropolitan Houston, and the area was experiencing a steady downturn in total
194 number of new COVID-19 cases (**Figure 1**). Delta VOCs slowly increased in frequency,
195 but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs
196 occurred (**Figure 1, Figure 2**), with an estimated doubling time of approximately seven
197 days. By September 20, the genome data showed that Delta VOCs accounted for
198 99.9% of all new COVID-19 cases in our health system (**Figure 2**). This represents the
199 fourth wave of COVID-19 cases in metropolitan Houston (**Figure 1**).

200 During the study period 18,736 COVID-19 cases were diagnosed in our
201 healthcare system, and we sequenced 16,965 SARS-CoV-2 genomes, representing

202 91% of cases. We identified 13,043 patients (76.9% of the total sequenced) with Delta
203 VOCs (Table 1A). The majority (62%; 2,418 of 3,922) of the non-Delta COVID-19 cases
204 occurring during the study period were caused by the Alpha (UK B.1.1.7) VOC.

205 Consistent with extensive infections caused by Delta variants in Southeast Asia
206 and elsewhere ([https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
207 [surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed: August 18, 2021;
208 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed:
209 August 18, 2021)¹, several patients had very recent travel histories to countries with a
210 high prevalence of these VOCs, suggesting acquisition abroad and importation into
211 Houston. Sixty patients with Delta Plus (Delta plus the K417N spike amino acid
212 substitution) were identified.

213 To understand the geospatial distribution of Delta in metropolitan Houston, we
214 acquired patient metadata from the electronic medical record by standard informatics
215 methods, and home address zip codes were used to visualize virus spread (**Figure 2**).
216 Delta VOCs were widely distributed throughout metropolitan Houston, with 334 distinct
217 zip codes represented (**Figure 2**), indicative of the ability of Delta variants to spread
218 very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination
219 over time illustrated the rapid spread of these variants throughout the Houston
220 metroplex (**Figure 2**).

221

222 Delta Family Subvariants

223

224 A total of 1,236 subvariants was identified based on amino acid changes in spike
225 protein. The seven most common identified in our study are shown (**Figure 3**) and these
226 represented 73% of the 13,043 Delta samples. It is possible that the unexpectedly high
227 number of subvariants reflects several contributing factors, including the large
228 population sizes and genetic diversity of Delta globally, and multiple independent
229 introductions into the Houston area. Other factors that in principle may contribute to
230 subvariant generation and survival include high virus load in patients on initial diagnosis
231 (**Table 1**), infection of partially immunized hosts, and prolonged infections occurring in
232 relatively immunocompromised individuals¹⁰⁻¹⁶. In this regard, some of our patients had
233 a history of cancer and organ transplants (**data not shown**). Patients infected with the
234 same subvariant usually lived in different zip codes and generally had no apparent
235 epidemiological link, consistent with the ability of Delta to spread very rapidly. In some
236 cases there were clear epidemiologic links between patients infected with the same
237 subvariant, including being members of the same household.

238 There is a considerable lack of detailed information about patients in the United
239 States with COVID-19 caused by Delta VOCs
240 (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021>,
241 [13-july-2021](#), last accessed August 18, 2021). Compared to all other patients in the time
242 frame studied, there was no significant difference in sex, but patients infected with Delta
243 were significantly but modestly younger (**Table 1**). However, Delta variant patients were
244 admitted significantly less frequently than other patients and had a significantly longer
245 median hospital length of stay, but there was no significant difference in mortality rate
246 (**Table 1**). Delta cases were more likely to be Asian (consistent with multiple recent

247 entry points from abroad) and Caucasian and less likely to be Hispanic or Latino, have
248 significantly lower PCR cycle threshold (Ct) values on initial diagnosis (a proxy for
249 higher virus load, a finding consistent with increased transmissibility of Delta variants).
250 In addition, Delta variants caused a significantly much higher rate of vaccine
251 breakthrough cases (23.7% compared to 6.6% for all other variants combined) (**Table**
252 **1**). Consistent with Delta causing an increased number of vaccine breakthrough cases,
253 it has been reported that this variant has reduced sensitivity to antibody neutralization *in*
254 *vitro*¹⁴.

255

256 Comparison of Delta and Alpha COVID-19 Cases

257

258 The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the
259 Alpha VOC (**Figure 1**) provided the opportunity of compare and contrast large disease
260 waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we
261 included Alpha VOC cases beginning January 1, 2021, because that time was soon
262 after our first recorded Houston Methodist case caused by this variant. The number of
263 Delta cases studied (n = 13,043) was much greater than the number of Alpha cases (n
264 = 3,238) (**Table 2**). The two patient populations differed significantly in many
265 characteristics, including median age, ethnicity, median PCR Ct level, admission rates,
266 maximum respiratory support, rate of vaccine breakthrough, median length of stay, and
267 mortality (**Table 2**).

268

269 Vaccine Breakthrough Cases

270

271 We next analyzed vaccine breakthrough cases (**Table 3**). We found 3,346 of the 16,965
272 total patients (19.7%) for whom we have genome sequence data met the CDC definition
273 of vaccine breakthrough cases (**Table 1 and Table 3**). There was no simple relationship
274 between the time elapsed since administration of the second booster vaccination and
275 the date of vaccination breakthrough (data not shown). These 3,346 patients received
276 either the Pfizer-BioNTech BNT162b2 ($n = 2,829$, 85%), Moderna mRNA-1273 ($n =$
277 365 , 11%), or J&J/Janssen JNJ-78436735 ($n = 147$, 4%) vaccine; vaccine type was not
278 specified for five individuals. This distribution generally reflects the great majority of
279 BNT162b2 vaccination doses given in our health system and should not be interpreted
280 to mean that the Pfizer-BioNTech and Moderna products are unusually prone to
281 breakthrough cases, as these mRNA vaccines are highly efficacious^{6, 17-23}. Vaccinated
282 patients infected with non-Delta variants had a significantly higher Ct value on initial
283 diagnosis, likely indicating better vaccine protection, lower virus load, and decreased
284 probability of transmission. Compared to all other variants combined, a significantly
285 lower percentage (25.9% compared to 37.2%; $P=0.0001$) of patients with breakthrough
286 cases caused by Delta variants was admitted to the hospital (**Table 1 and Table 3**).

287

288 Lambda and Mu Variants of Interest

289

290 The Lambda variant of interest was first reported in November 2020. It has very recently
291 attracted widespread media and public interest because it has caused large numbers of
292 infections in Peru and Ecuador, and has been reported to cause COVID-19 in the U.S²⁴,

293 ²⁵ (<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>, last accessed
294 September 2, 2021). There has been speculation that Lambda may become numerically
295 prominent in the United States and other countries, in part because its spike protein
296 differs immunologically and has been reported to be partially resistant *in vitro* to
297 vaccine-induced sera and therapeutic monoclonal antibodies²⁶⁻²⁸. Because of this
298 concern, we inspected our large genome sequence database to determine if Lambda
299 was present, and if so, had it increased substantially in the Houston metropolitan region.
300 The analysis identified only eight cases caused by this variant of interest, the first one
301 identified in our Houston Methodist patient population in mid-July 2021 (**Figure 4A**).
302 These patients lived in several non-contiguous zip codes throughout the metroplex, that
303 is, were not restricted to a single geographic area of greater Houston (**Figure 4A, B**).
304 The Mu VOI was initially identified in Colombia in January, 2021, and has been reported
305 to account for 39% of cases in that country²⁹. Mu also has been found in many other
306 countries worldwide, and recently it was reported that the Mu variant has increased
307 resistance *in vitro* to antibodies elicited by vaccination with BNT162b2 and natural
308 infection by SARS-CoV-2³⁰. We identified 53 cases of COVID-19 caused by the Mu
309 VOI, and similar to the Lambda these cases were distributed in multiple areas in the
310 Houston metropolitan region (**Figure 4C, D**).

311

312 **Discussion**

313

314 In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient
315 characteristics for 16,965 patients, focusing on mid-March 2021 through late September
316 2021, a time frame in which there was total replacement of the previously dominant
317 Alpha (B.1.1.7) VOC by Delta family VOCs. During this six-month period, a substantial
318 increase in COVID-19 cases occurred in our healthcare system and throughout all of
319 the Houston metropolitan area, virtually all driven by rapid dissemination of the highly
320 contagious Delta family variants. The study was based predominantly on genome
321 sequence analysis of 16,965 SARS-CoV-2 samples from socioeconomically,
322 geographically, and ethnically diverse patients. Several key findings were made,
323 including (i) Delta family VOCs supplanted the Alpha VOC in a relatively short period of
324 time, (ii) regardless of vaccination status, on initial diagnosis, compared to patients
325 infected by other VOCs, patients infected by Delta VOCs had significantly lower Ct
326 values, likely indicating significantly higher viral load in the nasopharynx, (iii) Delta
327 caused significantly more vaccine breakthrough cases than other VOCs, (iv)
328 significantly fewer fully vaccinated individuals required hospitalization, (v) the Lambda
329 and Mu VOIs were identified but were very rare, and they did not increase to substantial
330 levels in the time frame studied.

331 Our genome sequence data document a rapid increase of Delta variant cases in
332 metropolitan Houston and a corresponding decrease of COVID-19 cases caused by
333 Alpha and other variants, findings similar to epidemiologic trends observed in the UK
334 ([https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
335 13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)), last accessed August 18, 2021;
336 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions>

337 [anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021](#), last accessed
338 August 18, 2021). In less than five months, Delta VOCs increased from an initial
339 documented case in our large patient population to cause 99.9% of all cases in our
340 healthcare system. The rapid increase in Delta cases we documented is responsible for
341 a prominent fourth wave of COVID-19 disease in Houston that is ongoing (**Figure 1**).
342 Our findings are consistent with Delta VOCs epidemiologic data reported from other
343 regions of the US.

344 We found that Delta was significantly more likely to cause vaccine breakthrough
345 cases (**Table 1 and Table 3**). However, importantly, 19.7% of all of our 16,965 COVID-
346 19 cases with genome sequence data occurred in fully vaccinated individuals, but
347 importantly only a small number (n = 896; 5.3%) of these patients required
348 hospitalization. Vaccine breakthrough cases have emerged as an area of great interest,
349 especially so with the increasing percentage of COVID-19 cases caused by Delta
350 variants and the recognition that they are important causes of breakthroughs³¹⁻³⁶.
351 Although our analysis did not identify a simple relationship between the time elapsed
352 since administration of the second booster vaccination and the date of vaccination
353 breakthrough, this is an important area for continued study. Similarly, we did not study
354 the potential relationship between vaccination breakthrough and waning immunity, but
355 studies of this topic are ongoing.

356 Some investigators have speculated that the Lambda and Mu variants may
357 become a major concern in future surges. Although in principle this is possible, our data
358 show that neither variant has increased substantially in our metropolitan area during the

359 time frame studied. Thus, our genome analysis of a large set of samples from the first
360 nine months of 2021 does not currently support this speculation, although
361 circumstances may change in the future. Because we are sequencing the genome of
362 the great majority of SARS-CoV-2 causing COVID-19 in our diverse patient population,
363 we are continuously monitoring the growth trajectory of these and other variants in a
364 major metropolitan region in the US. Thus, our ongoing near-real-time sequencing of
365 SARS-CoV-2 genomes responsible for COVID-19 cases in metropolitan Houston
366 provides a facile strategy to assess changes in the virus population composition and
367 molecular evolution in this populous area.

368 Our study has several limitations that should be noted. Although we sequenced
369 the genomes of SARS-CoV-2 causing 91% of all Houston Methodist COVID-19 cases in
370 the study period, this sample represents only approximately 5% of cases reported in the
371 metropolitan region. We believe it is possible that our patient populations
372 underrepresent certain demographic groups, for example including homeless individuals
373 and pediatric patients. The great majority of the samples sequenced in this study were
374 obtained from symptomatic patients. Thus, it is possible that our sample failed to identify
375 virus genotypes that are preferentially represented in asymptomatic individuals.
376 However, given that at the end of the study Delta represented 99.9% of all cases, we
377 think it unlikely that variants associated with asymptomatic individuals would be
378 substantially different, although this is a formal possibility.

379 In the aggregate, our data add critical new information to the finding that these
380 three vaccines are highly efficacious in decreasing severe COVID-19 disease,

381 hospitalizations, and deaths^{6, 20, 23}. Further, the present study highlights the importance
382 of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and
383 stresses the need to continue to do this in near-real time as the pandemic continues,
384 the virus evolves, and new variants with potentially increased fitness are generated.
385 Analyses of this type are also important in the context of vaccine formulation and long
386 COVID, an increasing health and economic problem globally.

387

388

389 **Acknowledgments**

390

391 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha
392 Pejerrey for editorial contributions and Dr. Heather McConnell for help with figures. The
393 research was supported by the Houston Methodist Academic Institute Infectious
394 Diseases Fund and many generous Houston philanthropists. James J. Davis was
395 funded in whole or in part with Federal funds from the National Institute of Allergy and
396 Infectious Diseases, National Institutes of Health, Department of Health and Human
397 Services, under Contract No. 75N93019C00076. The funders had no role in the design
398 and conduct of the study; collection, management, analysis, and interpretation of the
399 data; preparation, review, or approval of the manuscript; and decision to submit the
400 manuscript for publication.

401 The findings and conclusions in this article are those of the authors and do not
402 necessarily reflect the views of the U.S. Army.

403 We declare that we have no conflict of interest.

404

405

406 **Author Contributions**

407

408 P.A.C., R.J.O., S.W.L., S.S., and J.M.M. had full access to all study data and take
409 responsibility for the integrity of the data and the accuracy of the data analysis; concept
410 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
411 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
412 by P.A.C.; funding obtained by J.M.M. and J.J.D.; overall supervision by J.M.M; P.A.C.,
413 R.J.O., and S.W.L. contributed equally and are co-first authors.

414

415

416 **Institutional Review Board statement:** This work was approved by the Houston
417 Methodist Research institutional review board (IRB1010-0199).

418

419

420 **Additional Information:** Genome data used in this study have been deposited to
421 GISAID.

422 **References**

423

424 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhojar RC, Fatihi S,
425 Datta M, Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V,
426 Singh MK, Imran M, Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V,
427 Chaudhary U, Thukral L, Pandey R, Dash D, Faruq M, Lall H, Gogia H, Madan P,
428 Kulkarni S, Chauhan H, Sengupta S, Kabra S, Consortium TIS-C-G, Singh SK, Agrawal
429 A, Rakshit P: Genomic characterization and Epidemiology of an emerging SARS-CoV-2
430 variant in Delhi, India. medRxiv 2021:2021.06.02.21258076.

431 [2] Hacısuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-
432 Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC,
433 Hatzioannou T, Bieniasz PD, Darnell RB: Vaccine Breakthrough Infections with SARS-
434 CoV-2 Variants. N Engl J Med 2021, 384:2212-8.

435 [3] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Neshet L, Stein M,
436 Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad
437 H, Rahav G, Wiener-Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of
438 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021.

439 [4] COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States,
440 January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021, 70:792-3.

441 [5] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R,
442 Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron
443 O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M,
444 Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A:

445 Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in
446 BNT162b2-mRNA-vaccinated individuals. *Nat Med* 2021, Aug;27(8):1379-1384.

447 [6] Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM,
448 Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager
449 DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning
450 DJ, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CT, Busse L, Ten
451 Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C,
452 Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Luring AS, Grijalva
453 CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart
454 KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH:
455 Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations
456 in the United States. *Clin Infect Dis* 2021.

457 [7] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,
458 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,
459 Musser JM: Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome
460 Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence
461 and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. *Am J*
462 *Pathol* 2021, 191:983-92.

463 [8] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,
464 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd
465 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of
466 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,

467 Texas, January through May 2021, Based on 12,476 Genome Sequences. *Am J Pathol*
468 2021, 191(10):1754-1773.

469 [9] Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, Shukla M, Subedi S,
470 Stevens R, Musser JM: Analysis of the ARTIC version 3 and version 4 SARS-CoV-2
471 primers and their impact on the detection of the G142D amino acid substitution in the
472 spike protein. *bioRxiv* 2021:2021.09.27.461949.

473 [10] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic
474 V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J: SARS-CoV-2 evolution in an
475 immunocompromised host reveals shared neutralization escape mechanisms. *Cell*
476 2021, 184:2605-17.e18.

477 [11] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo
478 HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins
479 M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S,
480 Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD,
481 Seaman MS, Cernadas M, Li JZ: Persistence and Evolution of SARS-CoV-2 in an
482 Immunocompromised Host. *N Engl J Med* 2020, 383:2291-3.

483 [12] Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus
484 CE, Adams M, Washer L, Martin ET, Luring AS: Prolonged Severe Acute Respiratory
485 Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. *J Infect Dis*
486 2021, 223:23-7.

487 [13] Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps
488 A, Sobolewski MD, Rennick LJ, Macatangay BJC, Klammer-Blain C, Kitsios GD, Methé B,
489 Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee J,

490 Sethi R, Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Vignali DA, Duprex WP, Agha
491 ME, Mellors JW, McCormick KD, Morris A, Haidar G: Intractable Coronavirus Disease
492 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2
493 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy
494 Recipient: A Case Study. *Clinical Infectious Diseases* 2021, 73(3):e815-e821.

495 [14] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM,
496 Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le
497 Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H,
498 Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey
499 FA, Schwartz O: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
500 neutralization. *Nature* 2021, 596(7871):276-280.

501 [15] Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A: SARS-CoV-2
502 evolution during treatment of chronic infection. *Nature* 2021, 592:277-82.

503 [16] Ghedin E, Nussenblatt V, Roder A, Das S, de Wit E, Youn J-H, Banakis S,
504 Muchegian A, Mederos C, Wang W, Chung M, Perez-Perez L, Palmore T, Brudno J,
505 Kochenderfer J: Year-long COVID-19 infection reveals within-host evolution of SARS-
506 CoV-2 in a patient with B cell depletion. *medRxiv* 2021:2021.10.02.21264267.

507 [17] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL,
508 Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury
509 K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A,
510 Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC: Safety
511 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of*
512 *Medicine* 2020, 383:2603-15.

513 [18] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector
514 SA, Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro
515 C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M,
516 Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C,
517 Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T: Efficacy and Safety of
518 the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2020, 384:403-16.

519 [19] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B,
520 Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-
521 Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie
522 L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath
523 PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD,
524 Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ,
525 Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi
526 YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy
527 MN, Rhead S, Schwarzbald AV, Singh N, Smith A, Song R, Snape MD, Sprinz E,
528 Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans
529 J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC,
530 Pollard AJ: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
531 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
532 Africa, and the UK. *Lancet* 2021, 397:99-111.

533 [20] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe
534 J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G,
535 Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M: Effectiveness of

- 536 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021, 385:585-
537 594.
- 538 [21] Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19
539 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* 2021, 385:187-9.
- 540 [22] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch
541 M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
542 Vaccination Setting. *N Engl J Med* 2021, 384:1412-23.
- 543 [23] Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M,
544 Nutalapati C, Kulkarni A, Mukherjee P, Zaveri L, Team CC-, Team AHC-Vs, Tallapaka
545 KB, Reddy DN: Clinical outcomes in vaccinated individuals hospitalized with Delta
546 variant of SARS-CoV-2. *medRxiv* 2021:2021.07.13.21260417.
- 547 [24] Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena
548 L, Morales Ruiz S, Acedo S, Lizarraga W, Bailon H, Cáceres O, Galarza M, Rojas-
549 Serrano N, Vargas-Herrera N, Lope-Pari P, Huayra J, Solari L: Genomic analysis
550 reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in
551 Peru despite circulation of variants of concern. *J Med Virol* 2021, 1-5.
- 552 [25] Romero PE, Dávila-Barclay A, Salvatierra G, González L, Cuicapuza D, Solis L,
553 Marcos-Carbajal P, Huancachoque J, Maturrano L, Tsukayama P: The Emergence of
554 SARS-CoV-2 Variant Lambda (C.37) in South America. *medRxiv*
555 2021:2021.06.26.21259487.
- 556 [26] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR: The Spike
557 Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial

558 Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv
559 2021:2021.05.14.444076.

560 [27] Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y,
561 Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Takaori-Kondo A, Arase
562 H, Consortium TGtPJ, Saito A, Nakagawa S, Sato K: SARS-CoV-2 Lambda variant
563 exhibits higher infectivity and immune resistance. bioRxiv 2021:2021.07.28.454085.

564 [28] Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, Liu J, Chen Z, Waheed
565 H, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: The Lambda
566 variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.
567 bioRxiv 2021:2021.08.25.457692.

568 [29] Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro
569 JA, Prada DA, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J,
570 Santamaría G, Rivera J, Rojas P, Ortiz JH, Cardona A, Malo D, Prieto-Alvarado F,
571 Gómez FR, Wiesner M, Martínez MLO, Mercado-Reyes M. Characterization of the
572 emerging B.1.621 variant of interest of SARS-CoV-2. *Infect Genet Evol.* 2021,
573 95:105038.

574 [30] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A,
575 Consortium TGtPJ, Nakagawa S, Sato K: Ineffective neutralization of the SARS-CoV-2
576 Mu variant by convalescent and vaccine sera. bioRxiv 2021:2021.09.06.459005.

577 [31] Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N,
578 Foreman A, Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B,
579 Park DJ, Siddle KJ, Harik V, Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS:
580 Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough

581 Infections, Associated with Large Public Gatherings - Barnstable County,
582 Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021, 70:1059-62.

583 [32] Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, Cui L,
584 Kalimuddin S, Chia WN, Tan CW, Ann Chai LY, Tan SY, Zheng S, Pin Lin RT, Wang L,
585 Leo Y-S, Lee VJ, Lye DC, Young BE: Virological and serological kinetics of SARS-CoV-
586 2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv
587 2021:2021.07.28.21261295.

588 [33] Sheikh A, McMenemy J, Taylor B, Robertson C: SARS-CoV-2 Delta VOC in
589 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet
590 2021, 397:2461-2.

591 [34] Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian
592 A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH,
593 Friedrich TC, Grande KM: Shedding of Infectious SARS-CoV-2 Despite Vaccination.
594 medRxiv 2021:2021.07.31.21261387.

595 [35] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal
596 Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y,
597 Regev-Yochay G: Covid-19 Breakthrough Infections in Vaccinated Health Care
598 Workers. N Engl J Med 2021.

599 [36] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo
600 R, Alroy-Preis S, Ash N, Huppert A: Waning immunity of the BNT162b2 vaccine: A
601 nationwide study from Israel. medRxiv 2021:2021.08.24.21262423.

602

603

604 **Figure Legends**

605

606 **Figure 1** Epidemiologic curve showing four COVID-19 disease waves in Houston

607 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-

608 three-day moving average. Each of the four waves is shown in a different color simply

609 as a stylistic device. The first and second waves were composed of a heterogenous

610 array of SARS-CoV-2 genotypes. The Alpha variant shown in the third wave and the

611 Delta variant shown in the fourth indicate their numeric prominence in those waves, and

612 should not be interpreted to mean that all cases in the third and fourth waves were

613 caused by Alpha and Delta VOCs, respectively. The fourth wave shown includes data

614 through September 20, 2021. The figure was generated with Tableau version 2020.3.4

615 (Tableau Software, LLC, Seattle, WA). The curve mirrors that of disease activity in

616 metropolitan Houston, Texas.

617

618 **Figure 2** Increase in Delta frequency over time and distribution in metropolitan

619 Houston. The study time frame was March 15, 2021 through September 20, 2021. **A:**

620 Cumulative increase in Delta during the study period; y-axis is the cumulative number of

621 new COVID-19 cases. At the end of the study period, Delta continuously caused 99.9%

622 of all COVID-19 cases. **B – E:** Geospatial distribution of Delta based on home address

623 zip code for each patient. **B:** April 15 – May 15; **C:** April 15 – June 15; **D:** April 15 – July

624 15; **E:** April 15 – August 15; **F:** April 15 – September 20. Note differences in heat map

625 scale for each panel. Figures were generated using Tableau version 2020.3.4. (Tableau

626 Software, LLC, Seattle, WA).

627

628 **Figure 3** Structural changes present in spike protein of the seven most abundant Delta
629 subvariants identified in the study. The numbers denote the number of patients with
630 each subvariant identified in this study. These seven subvariants represented 73% of
631 the 13,043 Delta samples identified in the study. In this figure, we included all
632 subvariants represented by at least 100 samples. S1-NTD, S1 domain-aminoterminal
633 domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain.
634 The figure is a modified version of one published previously⁸.

635

636 **Figure 4** Lambda and Mu variants identified in metropolitan Houston in our patient
637 population. **A:** cumulative increase in the cases caused by Lambda variants identified in
638 the study; **B:** geospatial distribution of these Lambda variants based on the home
639 address zip code for each patient. **C:** cumulative increase in cases caused by the Mu
640 variants identified in the study; **D:** geospatial distribution of the Mu variants based on
641 the home address zip code for each patient. Figures were generated using Tableau
642 version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

643 **Table 1. Summary of pertinent patient metadata for the 16,965 unique patients**

	Delta Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	13043 (76.9%)	3922 (23.1%)	16965	
Patient Characteristics				
Median Age (Years)	46.7	47.9	47.0	$P=0.0114$ Mann-Whitney
Female	6986 (53.6%)	2033 (51.8%)	9019 (53.2%)	$P=0.0578$ Fisher's exact test
Male	6057 (46.4%)	1889 (48.2%)	7946 (46.8%)	
Ethnicity				
Caucasian	5657 (43.5%)	1533 (39.4%)	7190 (42.6%)	$P<0.0001$ Chi-square
Hispanic or Latino	3395 (26.1%)	1199 (30.8%)	4594 (27.2%)	
Black	2908 (22.4%)	913 (23.4%)	3821 (22.6%)	
Asian	493 (3.8%)	113 (2.9%)	606 (3.6%)	
Native American	24 (0.2%)	15 (0.4%)	39 (0.2%)	
Hawaiian/Pacific Islander	32 (0.2%)	6 (0.2%)	38 (0.2%)	
Unavailable	492 (3.8%)	116 (3.0%)	608 (3.6%)	
BMI				
Median BMI	29.6	30.3	29.8	$P<0.0001$ Mann-Whitney
Admission Data				
Admitted	5184 (39.7%)	2118 (54.0%)	7302 (43.0%)	$P<0.0001$ Fisher's exact test
Not Admitted	7859 (60.3%)	1804 (46.0%)	9663 (57.0%)	
				Odds Ratio: 0.554 (95% CI 0.511- 0.600)
Median LOS (Days)	5.7	5.0	5.3	$P<0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	16 (0.3%)	7 (0.3%)	23 (0.3%)	$P<0.0001$ Chi-square
Mechanical Ventilation	555 (10.7%)	167 (7.9%)	722 (9.9%)	

Non-Invasive Ventilation	501 (9.7%)	187 (8.8%)	688 (9.4%)	
High Flow Oxygen	1450 (28.0%)	402 (19.0%)	1852 (25.4%)	
Low Flow Oxygen	1741 (33.6%)	876 (41.4%)	2617 (35.8%)	
Room Air	921 (17.8%)	479 (22.6%)	1400 (19.2%)	
Mortality				
Alive	12496 (95.8%)	3755 (95.7%)	16251 (95.8%)	$P=0.8561$
Deceased	547 (4.2%)	167 (4.3%)	714 (4.2%)	Fisher's exact test
				Odds Ratio: 0.896 (95% CI 0.739- 1.087)
Median PCR Cycle Threshold				
Abbott Alinity	21.0 n=4200	25.6 n=1408	n=5608	$P<0.0001$ Mann-Whitney
Hologic Panther	21.9 n=1140	26.0 n=473	n=1613	$P<0.0001$ Mann-Whitney
Vaccine				
No vaccine	9483 (72.7%)	3509 (89.5%)	12992 (76.6%)	$P<0.0001$
>7 days past 1st vaccine	472 (3.6%)	155 (4.0%)	627 (3.7%)	Chi-square
>14 days past 2nd vaccine	3088 (23.7%)	258 (6.6%)	3346 (19.7%)	

644 Data include 16,965 unique patients with high-quality sequence results between March 15, 2021 and September 20,
 645 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of
 646 stay

647 **Table 2. Comparison of pertinent patient metadata for 16,281 unique Delta VOC**
 648 **and Alpha VOC patients**

	Delta Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	13043 (80.1%)	3238 (19.9%)	16281	
Patient Characteristics				
Median Age (Years)	46.7	49.4	47.3	$P < 0.0001$ Mann-Whitney
Female	6986 (53.6%)	1698 (52.4%)	8684 (53.3%)	$P = 0.2538$ Fisher's exact test
Male	6057 (46.4%)	1540 (47.6%)	7597 (46.7%)	
Ethnicity				
Caucasian	5657 (43.5%)	1269 (39.4%)	6926 (42.7%)	$P < 0.0001$ Chi-square
Hispanic or Latino	3395 (26.1%)	961 (29.8%)	4356 (26.9%)	
Black	2908 (22.4%)	757 (23.5%)	3665 (22.6%)	
Asian	493 (3.8%)	126 (3.9%)	619 (3.8%)	
Native American	24 (0.2%)	12 (0.4%)	36 (0.2%)	
Hawaiian/Pacific Islander	32 (0.2%)	4 (0.1%)	36 (0.2%)	
Unavailable	492 (3.8%)	91 (2.8%)	583 (3.6%)	
BMI				
Median BMI	29.6	30.5	29.8	$P < 0.0001$ Mann-Whitney
Admission Data				
Admitted	5184 (39.7%)	1721 (53.2%)	6905 (42.4%)	$P < 0.0001$ Fisher's exact test
Not Admitted	7859 (60.3%)	1517 (46.8%)	9376 (57.6%)	
Median LOS (Days)	5.7	5.1	5.4	$P = 0.0031$ Mann-Whitney
Max Respiratory Support				
ECMO	16 (0.3%)	7 (0.4%)	23 (0.3%)	$P < 0.0001$


Mechanical Ventilation	555 (10.7%)	155 (9.0%)	710 (10.3%)	Chi-square
Non-Invasive Ventilation	501 (9.7%)	165 (9.6%)	666 (9.6%)	
High Flow Oxygen	1450 (28.0%)	366 (21.3%)	1816 (26.3%)	
Low Flow Oxygen	1741 (33.6%)	705 (41.0%)	2446 (35.4%)	
Room Air	921 (17.8%)	323 (18.8%)	1244 (18.0%)	
Mortality				
Alive	12496 (95.8%)	3073 (94.9%)	15569 (95.6%)	$P=0.0271$
Deceased	547 (4.2%)	165 (5.1%)	712 (4.4%)	Fisher's exact test
				Odds Ratio: 0.815 (95% CI 0.682- 0.975)
Median PCR Cycle Threshold				
Abbott Alinity	21.0 n=4200	22.4 n=1101	n=5301	$P=0.0004$ Mann-Whitney
Hologic Panther	21.9 n=1140	24.3 n=374	n=1514	$P<0.0001$ Mann-Whitney
Vaccine				
No vaccine	9483 (72.7%)	2969 (91.7%)	12452 (76.5%)	$P<0.0001$
>7 days past 1st vaccine	472 (3.6%)	133 (4.1%)	605 (3.7%)	Chi-square
>14 days past 2nd vaccine	3088 (23.7%)	136 (4.2%)	3224 (19.8%)	


649 Data include 16,281 unique patients with high-quality sequence results between January 1, 2021 and September 20,
650 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of
651 stay

652 **Table 3. Summary of pertinent patient metadata for the 3,346 fully vaccinated**
 653 **patients**

	Vaccinated	Not Vaccinated	Total	Statistical Analysis
Median PCR Cycle Threshold				
Abbott Alinity	20.5 n=1244	22.1 n=4364	n=5608	P=0.0018 Mann-Whitney
Hologic Panther	22.2 n=378	23.5 n=1235	n=1613	P=0.0348 Mann-Whitney
Admission Data				
Admitted	896 (26.8%)	6406 (47.0%)	7302 (43.0%)	P<0.0001 Fisher's exact test Odds Ratio: 0.412 (95% CI 0.379-0.448)
Not Admitted	2450 (73.2%)	7213 (53.0%)	9663 (57.0%)	
Delta Variant				
	Delta Variant	Other Variants	Total	
No. (%) with data	3088 (92.3%)	258 (7.7%)	3346	
Admission Data				
Admitted	800 (25.9%)	96 (37.2%)	896 (26.8%)	P=0.0001 Fisher's exact test Odds Ratio: 0.590 (95% CI 0.453-0.769)
Not Admitted	2288 (74.1%)	162 (62.8%)	2450 (73.2%)	

654





S1-NTD**S1-RBD****S1****S2**